

**CD4⁺ T Helper T Cells and Types 1, 2, and 3 Immunity;
*Cytokines in immune defense and disease***

**Andrew Lichtman M.D., Ph.D.
Brigham and Women's Hospital
Harvard Medical School**



BWH



HMS


Lecture outline

- Overview of T cell responses and T cell mediated immunity
- Discovery and definition of Th subsets
- Functions of subsets and roles in human disease –simple view
- Additional complexity: hybrid subsets, plasticity, new ways of considering Th heterogeneity--Types 1, 2, 3 immunity
- Therapeutic targeting of subset cytokines for inflammatory diseases

Types of T Cell–Mediated Immune Reactions


CD4+ helper T cells (Th)

Microbes that live inside phagocytes
Microbes that are readily killed by phagocytes




CD8+ Cytotoxic T lymphocytes (CTL)


Microbes that live inside tissue cells



Steps in a CD4+ Helper T Cell Response











Cytokine-Mediated Functions of CD4+ Helper T Cells




CD4+ Helper T cell subsets: Definitions and Properties

- Populations of CD4+ T cells that are distinguished by producing a restricted and non-overlapping set of cytokines
 - Early after activation, T cells can produce a broad array of cytokines
 - Progressive activation leads to “polarization”; production of selected cytokines
- Distinct functions, migration properties, roles in disease
- Can be identified by gene or protein expression of:
 - Cytokines
 - Trafficking molecules (chemokine receptors)
 - “Master” transcriptional regulators

Subsets of CD4+ Th Cells


Effector T cells	Defining cytokines	Principal target cells	Major immune reactions	Host defense	Role in disease
Th1 	IFN- γ	Macrophages 	Macrophage activation	Intracellular pathogens	Autoimmunity; chronic inflammation
Th2 	IL-4 IL-5 IL-13	Eosinophils 	Eosinophil and mast cell activation; alternative macrophage activation	Helminths	Allergy
Th17 	IL-17 IL-22	Neutrophils 	Neutrophil recruitment and activation	Extracellular bacteria and fungi	Autoimmunity; inflammation
Tfh 	IL-21 (and IFN- γ or IL-4)	B cells 	Antibody production	Extracellular pathogens	Autoimmunity (autoantibodies)

CD4 Effector T Cell Subsets




Differentiation of Th Subsets


Different subsets develop from uncommitted naïve CD4+ T cells



Each subset is induced by the types of microbes that subset is best able to combat



Cytokines produced at the site of antigen recognition drive differentiation into one or the other subset




Major sources of cytokines that drive differentiation: APCs, responding T cells themselves, other host cells

Differentiation of Th Subsets


- Signaling induced by:
 - Antigen via TCR
 - Costimulation via Costim receptor
 - Cytokines via cytokine receptors
- Activation of transcription factors
 - STATs
 - Master regulators
- Epigenetic changes at loci encoding master regulators and cytokine

Differentiation of Th Subsets


Th1



Th17



Th2



JAK-STAT Cytokine Signaling

JAKS

Jak1

Jak2

Jak3

Tyk2

STATS

STAT1


STAT2

STAT3



STAT4

STAT5 (A and B)

STAT6




The Functions of Th1 Cells: Macrophage Activation




Human T_H1 cells: defense against intracellular microbes


- **Mendelian susceptibility to mycobacterial disease (MSMD):** inborn errors of IFN- γ mediated immunity
 - Mutations in genes encoding **IL-12 receptor, IL-12, IFN- γ receptor, IFN- γ signaling molecules**
- Most common infections are with microbes that can live inside phagocytes: *Mycobacteria*, *Salmonella*
- ***IL-12 and IFN- γ required for Th1 differentiation; IFN- γ required for Th1 function (macrophage activation)***




Mycobacteria





Salmonella



Functions of T_H17 cells




STAT3-dependent cytokines in Th17 differentiation



Burkett PR, Meyer zu Horste G, Kuchroo VK. J Clin Invest. 2015;125:2211-9

Human T_H17 cells: defense against extracellular microbes

- Human Stat3 mutations result in **HIES***, characterized by infections, as well as many other clinical manifestations
 - Recurrent staphylococcal abscesses or mucocutaneous candidiasis
- HIES patients have impaired T_H17 responses
- Supports role for T_H17 cells in resistance to extracellular bacterial and fungal infections



Milner JD et al
Nature 452, 773-776. 2008


*Hyper-IgE Syndrome, aka Job's syndrome

What are the functions of human Th1 vs. Th17 cells?


- Mendelian susceptibility to mycobacterial disease (MSMD): inborn errors of IFN- γ immunity.
- Some genes involved: IL-12R β 1, IFN- γ R1, IL-12p40, IFN- γ R2, STAT-1, IRF8,
- Most common infections with deficiencies in IFN- γ R and STAT1: *BCG, environmental mycobacteria, M. tuberculosis, Salmonella*
- Most common infections with deficiencies of IL-12p40, IL-12R β 1: *Mycobacteria, Salmonella, Candida*

Why both intracellular and extracellular infections in IL-12p40 and IL-12R β 1 deficiencies?

- p40 shared by IL-12 and IL-23
- IL-12R β 1 shared by both IL-12R and IL-23R
- IL-12 needed for Th1 differentiation
- IL-23 needed for Th17 differentiation




Implications for mAb drug therapies




Functions of T_H2 Cells

Macrophage Activation: Classical & Alternative



Th differentiation:

Summary of Cytokines and Transcription Factors Involved



The real story about Th subsets is more complicated!


- *Additional subsets related to classic subsets*
- *Other sources of the same helper cytokines besides CD4+ Th cells*
- *CD4+ Th cells that blur Th 1, 2, 17 distinctions*
- *Plasticity of Th subsets*

Th cells that make both IL-17 and IFN- γ are important in defense and disease

- Bi-allelic loss-of-function mutations in *RORC* (encodes ROR γ T) result in **candidiasis** and **mycobacteriosis**[#]
- Patients lack **IL-17A/F-producing T cells** (expected)...explains candidiasis
- Patients also have impaired **IFN- γ response** to mycobacterium (unexpected).
- IFN- γ production is impaired in Th1* (a.k.a “nonclassic Th17) subset: $\alpha\beta$ TCR, CD4⁺ T bet⁺ ROR γ T⁺ IFN- γ ⁺, IL-17A⁺ CCR6⁺, CXCR3⁺


Dual IFN γ /IL-17 producing Th cells (Th1*) may be the major pathogenic effectors in many diseases[#]

- Can be derived from already differentiated classic Th17 cells in response to **IL-23**
- More abundant than Th1 or Th17 at sites of inflammation in mouse model diseases (EAE) and human diseases (Crohn's, atherosclerosis)



Innate Lymphoid Cells

- *No T cell or B cell antigen receptors*
- *Activated by cytokines*
- *Effector functions mediated by cytokines*
- *Subsets analogous to helper T cell subsets*
- *Present in tissues before infection-- contribute to early cytokine responses in host defense and inflammatory diseases*




Other sources of the same helper cytokines besides CD4+ Th cells

Non-Th17 Sources of IL-17 in Inflammatory Diseases

- **$\gamma\delta$ T cells: Psoriasis**
- **CD8+ T cells: Psoriasis**
- **Neutrophils: Arthritis, Dermatitis**
- **iNKT cells: Various**
- **ILCs: Inflammatory bowel disease**

Anti-IL-17 therapy would theoretically apply to of all of these

Types 1, 2 and 3 Immunity Model based on Target cells



- Type 1 cells that primarily activate and attract mononuclear phagocytes such as monocytes, macrophages and DCs (Th1, ILC1, NK, CTL)
- Type 2 cells targeting B cells, mast cells, basophils, and eosinophils (Th2, TH9, ILC2,)
- Type 3 cells acting on non-hematopoietic cells at barrier tissue sites, including epithelial cells and stromal cells (Th17, ILC3, Th22, CD8 T cells)

Orbital model based on TH cell targets

Targeting Type 1, 2 and 3 Diseases

Type 1

- IFN- γ : Primary HLH (Emapalumab)
- IL-12 p40: Crohn's (Ustekinumab)

Type 3


- IL-17A: Psoriasis, RA, Ankylosing spondylitis (Secukinumab,)
- IL-17RA: Psoriasis, Psoriatic arthritis (Brodalumab)
- IL-23 p19 Psoriasis (Guselkumab, Tildrakizumab, Risankizumab)

Type 1 and 3

- IL-23 and IL12 p40: Psoriasis, Psoriatic arthritis (Ustekinumab)

Type 2



- IL-5: Asthma (Mepolizumab)
- IL-4R α Receptor: Atopic dermatitis (Dupilumab)
- TSLP: Asthma (Tezepelumab)



Blocking the production or action of cytokines

Remarkable advances in treatment of many inflammatory diseases using mAbs that block cytokines or cytokine receptors

- Plaque psoriasis (PS) is a good example of one of those diseases.
- In PS Type 3 responses, dependent on IL-23 and characterized by IL-17, TNF and IL-22 mediated inflammation are dominant.
- Type 1 responses with interferon gamma production also contribute
- mAbs targeting IL-23, IL23R, and IL-17 are now in wide use to treat PS








JAK inhibitors (JAKinibs)

Jakinibs are small molecule inhibitors of JAKs that block ATP binding to the enzymes' active sites

Each Jakinib developed has a different range of specificities for the different JAKs

Specificities of Jakinibs in clinical use: pan JAK, JAK1/JAK2, JAK1



RA		Ruxolitinib (JAK1/2) Tofacitinib (JAK 1/2/3) Baricitinib (JAK 1/2) Upadacitinib (JAK1)
UC		Tofacitinib (JAK 1/2/3)
AD		Upadacitinib (JAK1) Abrocitinib (JAK1)

Selected References

- Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. *Drugs*. 2017
- Burkett PR, Meyer zu Horste G, and Kuchroo VK. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. *J Clin Invest*. 2015
- Bustamante J, Boisson-Dupuis S, Abel L, and Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. *Semin Immunol*. 2014
- Dong C Cytokine Regulation and Function in T Cells. *Annu. Rev. Immunol*. 2021; 39:51–76.
- Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. *Nat Immunol*. 2014
- Gadina G, Chisolm DA, Philips RL, McInness IB, Changelian PS and O’Shea JJ Translating JAKs to Jakinibs *J Immunol* 2020
- Hirahara K, Poholek A, Vahedi G, Laurence A, Kanno Y, Milner JD, et al. Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. *J Allergy Clin Immunol*. 2013
- Moghaddam AS, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization and function in health and disease. *J Cell Physiol*. 2018.
- McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. *Immunity*. 2019
- Schnell A, Littman DR, and Kuchroo VK. TH17 cell heterogeneity and its role in tissue inflammation. *Nat Immunol*. 2023
- Tuzlak, S. et al. Repositioning TH cell polarization from single cytokines to complex help. *Nat. Immunol*. (2021).